Access to Resources for Patients With PTEN Hamartoma Tumor Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

13 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-05-11

Study Completion Date

2019-09-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to gain a better understanding of access to clinical and research resources for families of children affected with a phosphatase and tensin homology (PTEN) mutation. Ultimately, the researchers hope to be able to use this information to develop a standard of care for affected individuals and their family members. Family members/legal guardians of an individual with a PTEN mutation enrolled in the Rare Diseases Clinical Research Network (RDCRN) Contact Registry will be invited via email to participate in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Research on the Environment and Children's Health: Retinoblastoma

NCT00582049

Retinoblastoma

COMPLETED

Outcomes Study of Late Effects After Proton RT for Pediatric Tumors of the Brain, Head, and Neck

NCT01067196

Central Nervous System Tumors

COMPLETED

Li-Fraumeni Syndrome Imaging Study

NCT03176836

Li-Fraumeni Syndrome

ENROLLING_BY_INVITATION NA

Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma

NCT04425434

Retinoblastoma

RECRUITING

A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes

NCT02439645

Long qt Syndrome Torsade de Pointes

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to investigate access to clinical care and clinical research for patients with PTEN hamartoma tumor syndrome. This research will entail an anonymous online survey sent to families/caretakers of affected children. The survey will inquire: (1) basic clinical information about the child, such as diagnoses (both genetic and neurodevelopmental), level of functioning (estimated IQ) (2) clinical specialists that the child sees or needs to see (3) how families learn about clinical trials/research relevant to their child (4) basic demographics about the parent/caretaker completing the survey.

Specifically, this survey will collect information pertaining to:

* Number of affected children in household
* PTEN mutation type of affected children
* Age and gender of affected children
* Age, neurodevelopmental disorders, medical problems, IQ, and access to clinical care (specialists currently being seen, specialists not able to see and why) of most affected child
* Research methods and mediums for disorder-specific treatment options for affected children
* Reasons behind not participating in clinical research options
* Facts (gender, age, if PTEN mutation carrier, work status, relationship to affected children, days per week of caregiving responsibilities, education level) about participant completing survey.

In total, the survey should take no more than 15 minutes to complete.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PTEN Gene Mutation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Family members, specifically a parent, legal guardian, or relative, of a child who meets the following:

* Age 3 to 17 years old at the time of survey completion
* Reported diagnosis of a PTEN mutation
2. Enrollment in the RDCRN Contact Registry